Efficacy and tolerability of 1-and 3-month leuprorelin acetate depot formulations (Eligard®/Depo-Eligard®) for advanced prostate cancer in daily practice: A Belgian prospective non-interventional study

Archives of Medical Science

Volumn 10, Issue 3, 2014, Pages 477-483

  Braeckman, Johan ^a   Michielsen, Dirk ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Leuprolide; Physician's practice patterns; Prospective studies; Prostatic neoplasms; Treatment outcome

Indexed keywords

ANTIANDROGEN; DEPO ELIGARD; ESTRAMUSTINE; GONADORELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BELGIUM; CLINICAL PRACTICE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HEMATOMA; HOT FLUSH; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE HEMATOMA; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PHASE 4 CLINICAL TRIAL; PHYSICIAN; PROSPECTIVE STUDY; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE; VERY ELDERLY;

EID: 84903625853     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2014.43743     Document Type: Article

References (16)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81.
2. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Update March 2013. Available from URL: http://www.uroweb.org/guidelines/ online- guidelines/. Accessed April 18th, 2013.
3. Depo-Eligard 7.5 mg Summary of Product Characteristics. (DEPO-ELIGARD 7,5 mg, poeder en oplosmiddel voor oplossing voor injectie.) Available from URL: http://www.bcfi.be/. Accessed April 18th, 2013.
4. Depo-Eligard 22.5 mg Summary of Product Characteristics. (DEPO-ELIGARD 22,5 mg, poeder en oplosmiddel voor oplossing voor injectie.) Available from URL: http://www.bcfi.be/. Accessed April 18th, 2013.
5. Depo-Eligard 45 mg Summary of Product Characteristics. (DEPO-ELIGARD 45 mg, poeder en oplosmiddel voor oplossing voor injectie.) Available from URL: http://www.bcfi.be/. Accessed April 18th, 2013.
6. Perez-Marrero R, Chu FM, Gleason D, Loizides E, Wachs B, Tyler RC. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002; 24: 1902-14.
7. Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC. A clinical study of 22.5 mg. LA-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002; 168: 1199-203.
8. Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006; 175: 533-6.
9. Tunn UW. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urol 2011; 11: 15.
10. Ouzaid I, Rouprêt M. Interest of a 6-month depot form of hormonotherapy in the treatment of advanced hormone dependent prostate cancer: results from the 'ELIRE'observational study. Prog Urol 2011; 21: 866-74.
11. Greil S, Robinson EA, Singal B, Kleer E. Efficacy over time of LHRH analogs in the treatment of PCa: a prospective analysis using serum testosterone to determine dosing intervals. Urology 2009; 73: 631-4.
12. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164: 726-9.
13. Morote J, Esquena S, Abascal JM, et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 2006; 77: 135-8.
14. Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178: 1290-5.
15. Dason S. Testosteron suppression: impact of testosterone level on disease progression in advanced prostate cancer. J Clin Oncol 2012; 30 (Suppl 5): 77 (abs. 46).
16. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010; 105: 648-51.